Benzinga | Nov 30, 2021 04:43PM EST

Redhill Biopharma Q3 EPS $(0.05) Beats $(0.21) Estimate, Sales $21.61M Miss $24.52M Estimate

Redhill Biopharma (NASDAQ:RDHL) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.21) by 76.19 percent. This is unchanged from the same period last year. The company reported quarterly sales of $21.61 million which missed the analyst consensus estimate of $24.52 million by 11.87 percent. This is a 3.18 percent increase over sales of $20.94 million the same period last year.